India, Sept. 25 -- The Government of India has issued a release:
The Production Linked Incentive (PLI) Scheme for Bulk Drugs is strengthening India's domestic capabilities in manufacturing critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs), reducing import dependence and enhancing resilience across the pharmaceutical supply chain.
Five Greenfield projects that have commissioned manufacturing facilities under the Scheme demonstrate the growing scale and diversity of domestic production, covering critical ingredients for antibiotics, cardiovascular medicines and Paracetamol.
Lyfius Pharma Pvt. Ltd., a subsidiary of Aurobindo Pharma Limited, has established a large-scale Penicillin ...